Skleo Health is a technology company.
Skleo Health has raised $4.0M across 1 funding round.
Skleo Health has raised $4.0M in total across 1 funding round.
Skleo Health has raised $4.0M in total across 1 funding round.
Skleo Health's investors include Antler, Nauta Capital, Peak, Mario Götze.
Skleo Health is a German health-tech startup founded in 2024 that provides AI-powered, six-minute eye screenings for early detection of preventable eye diseases like glaucoma, diabetic retinopathy, and AMD. It serves individuals in everyday locations such as opticians, pharmacies, retail stores, and workplaces, solving the problem of late diagnoses caused by inaccessible, time-consuming specialist care by offering rapid, non-invasive scans validated by CE-certified AI and specialist ophthalmologists.[1][2][3][4] The company has screened over 11,000 people across Germany's 50 largest cities, identifying more than 3,000 medically relevant cases, and recently raised €3M ($3.5M) in seed funding led by Sanoptis, Antler, and angels to scale to 30,000 screenings per month and build a nationwide platform connecting patients to specialists.[2][3][4][5]
This decentralized, "human + AI" model reduces healthcare system strain by freeing specialists for treatment, cutting costs, and enabling proactive prevention over reactive care.[1][2][4]
Skleo Health emerged from the Antler Founder Residency Program in Berlin, founded in March 2024 by a trio blending medical, technical, and business expertise: Dr. Steffen E. Künzel (ophthalmologist and scientist from Charité Berlin), Fabien Vogl (engineer and healthcare strategist from Air Liquide with an MBA), and Dr. Alex Hein (mathematician, economist, and ex-BCG consultant).[3][4][5] The idea stemmed from Dr. Künzel's clinical experience witnessing late-stage diagnoses limiting treatment options, inspiring a shift to proactive prevention by bringing certified screenings into daily life.[2][3][4]
Early traction was swift: within months, the company expanded to Germany's 50 largest cities, partnered with Mister Spex, pharmacy chains, employers, and retailers, screened 11,000 people, and detected 3,000 relevant findings, setting the stage for national scaling.[2][3][4]
Skleo Health rides the wave of AI-driven preventive healthcare and decentralization, addressing ophthalmology's core challenge: late diagnosis of treatable diseases amid specialist shortages and aging populations.[1][2][3] Timing aligns with Europe's push for efficient health systems post-pandemic, where scalable AI validation meets regulatory standards like CE certification, enabling mass adoption.[1][4] Market forces favoring it include rising demand for accessible care, investor interest in health-tech (e.g., Sanoptis backing), and partnerships with retail/pharmacy giants, positioning Skleo to influence ecosystems by setting norms for "screening-as-a-service" and reducing blindness rates across Europe.[2][3][4]
Skleo Health is primed to dominate decentralized eye care in Europe, leveraging its €3M seed to hit 30,000 monthly screenings, expand partnerships (e.g., major retailers), and launch its patient-specialist platform.[2][4] Trends like AI-health integration, preventive care mandates, and workplace wellness will accelerate growth, potentially evolving its influence toward pan-European rollout and new disease screenings. With strong clinical backing and early metrics, it could redefine accessible prevention, turning "a new vision for eye care" into millions saved from blindness.[1][2][6]
Skleo Health has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $4.0M Seed | Antler, Nauta Capital, Peak, Mario Götze |